- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01809743
Regadenoson and Adenosine
November 11, 2013 updated by: Lokien van Nunen
Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve
The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the gold standard)and to investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Noord-Brabant
-
Eindhoven, Noord-Brabant, Netherlands, 5623 EJ
- Catharina hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-80 years
- Scheduled for invasive measurement of FFR for diagnostic and interventional purposes in proximal or mid segments of a coronary artery
Exclusion Criteria:
- Severe aortic valve stenosis
- History of severe COPD
- Syncope or bradycardia (less than 50 beats/min)
- Known conduction disturbances (2nd-3rd degree heart-block, sick sinus without pacemaker or long QT-syndrome)
- Severe hypotension (RR <90 mmHg)
- Patients in whom no access to the coronary circulation can be obtained by the femoral artery or in whom femoral access was problematic
- Coronary anatomy not suitable for FFR measurement (extremely tortuous or calcified coronary vessels)
- Previous coronary bypass surgery
- Recent ST elevation myocardial infarction (<5 days)
- Recent non-ST elevation myocardial infarction (<5 days) if the peak CK is >1000 IU
- Inability to provide informed consent
- Pregnancy
- Use of methylxanthines (in the last 12 hours)
- Use of Dipyridamol (in the last 48 hours)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Regadenoson central - peripheral
First bolus regadenoson administered central, second bolus administered peripheral
|
To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the golden standard).
Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
|
ACTIVE_COMPARATOR: Regadenoson peripheral - central
First bolus regadenoson administered peripheral, second bolus administered central
|
Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the golden standard).
|
ACTIVE_COMPARATOR: Regadenoson central - central
First bolus regadenoson administered central, second bolus administered central
|
Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the golden standard).
|
ACTIVE_COMPARATOR: Regadenoson peripheral - peripheral
First bolus regadenoson administered peripheral, second bolus administered peripheral
|
Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the golden standard).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the accuracy of Regadenoson to induce maximal and steady state hyperemia
Time Frame: participants will be followed up during hospital stay, an expected average of 1 day
|
To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve.
(adenosine is considered to be the gold standard).
|
participants will be followed up during hospital stay, an expected average of 1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time intervals of maximum hyperemia
Time Frame: participants will be followed up during hospital stay, an expected average of 1 day
|
To investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.
|
participants will be followed up during hospital stay, an expected average of 1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nico H.J. Pijls, MD, PhD, Catharina Ziekenhuis Eindhoven
- Study Director: Lokien X van Nunen, MD, Catharina Ziekenhuis Eindhoven
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (ACTUAL)
October 1, 2013
Study Completion (ACTUAL)
October 1, 2013
Study Registration Dates
First Submitted
December 18, 2012
First Submitted That Met QC Criteria
March 11, 2013
First Posted (ESTIMATE)
March 13, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
November 13, 2013
Last Update Submitted That Met QC Criteria
November 11, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine A2 Receptor Agonists
- Adenosine
- Regadenoson
Other Study ID Numbers
- NL42049.060.12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Regadenoson central - peripheral
-
University of NebraskaGE Healthcare; Astellas Pharma US, Inc.CompletedCoronary Artery Disease | Myocardial Perfusion AbnormalitiesUnited States
-
Brigham and Women's HospitalCompletedCoronary Artery DiseaseUnited States
-
Ochsner Health SystemAstellas Pharma Global Development, Inc.CompletedCoronary Artery DiseaseUnited States
-
University of Colorado, DenverCompletedCoronary Artery Disease | Type 1 Diabetes MellitusUnited States
-
VersitiDana-Farber Cancer Institute; University of Illinois at Chicago; Medical College... and other collaboratorsUnknownSickle Cell Disease | Sickle Cell AnemiaUnited States
-
St. Louis UniversityAstellas Pharma US, Inc.; University of FloridaCompletedCoronary Artery DiseaseUnited States
-
University of CincinnatiCompletedCoronary Artery DiseaseUnited States
-
University of Maryland, BaltimoreAstellas Pharma US, Inc.CompletedCardiac FunctionUnited States
-
University of ChicagoAstellas Pharma IncCompleted
-
University of Alabama at BirminghamAstellas Scientific & Medical Affairs, Inc.CompletedSudden Cardiac Death | Left Ventricular Systolic DysfunctionUnited States